{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:53:54Z","timestamp":1769604834726,"version":"3.49.0"},"reference-count":26,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflamm Intest Dis"],"published-print":{"date-parts":[[2024]]},"abstract":"<b><i>Introduction:<\/i><\/b> Collagenous colitis (CC) is a disabling disease primarily affecting elderly women. Sparse, well-documented treatment modalities exist, except for budesonide. Long-term and repetitive treatment with budesonide is often necessary. Rifaximin is a poorly absorbed antibiotic with a positive modulatory effect on gut microbiota. In this randomised, double-blind, placebo-controlled single-centre trial, we test the effect of adding rifaximin in continuation to budesonide on relapse rates in CC. <b><i>Methods:<\/i><\/b> Eligible patients with active, biopsy-verified CC received oral budesonide during a 6-week open-label induction phase. Patients in clinical remission after 4 weeks of treatment were randomised to receive either rifaximin or placebo for 4 weeks. <b><i>Results:<\/i><\/b> Fifteen patients were randomised to receive either rifaximin (<i>n<\/i> = 7) or placebo (<i>n<\/i> = 8). At 12-week follow-up, 2 patients in the rifaximin group were still in remission and none in the placebo group (<i>p<\/i> = 0.2). The median number of days in remission in the rifaximin group was 42 (interquartile range [IQR] 33\u2013126) compared to 18.5 (IQR 10.5\u201351.5) in the placebo group (<i>p<\/i> = 0.189). At 12-week follow-up, the relapse rate per 100 person-days in the placebo group was higher (3.25 [1.40\u20136.41]) than in the rifaximin group (1.33 [0.43\u20133.10]). <b><i>Conclusion:<\/i><\/b> Although not statistically significant (<i>p<\/i> = 0.0996), the study suggests a potential improvement in relapse rates within the rifaximin group compared to the placebo group. A major limitation in the study is the small sample size. <\/jats:p>","DOI":"10.1159\/000536124","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T22:00:31Z","timestamp":1706133631000},"page":"22-28","source":"Crossref","is-referenced-by-count":1,"title":["Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1159","volume":"9","author":[{"given":"Sabine","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise B.","family":"Grode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole K.","family":"Bonderup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.940378"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/his.12592"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.2.248"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.156513"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000143"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308956"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.05.014"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000065"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90332-1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i7.1319"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.30295"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02688.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36042"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308363"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13928"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004409"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1186639"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq345"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i42.4643"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20977"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20255"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003575.pub5"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000438135.88681.98"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i25.4491"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12735"}],"container-title":["Inflammatory Intestinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/iid\/article-pdf\/9\/1\/22\/4168620\/000536124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/iid\/article-pdf\/9\/1\/22\/4168620\/000536124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:04:39Z","timestamp":1745424279000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000536124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000536124","archive":["Portico"],"relation":{},"ISSN":["2296-9403","2296-9365"],"issn-type":[{"value":"2296-9403","type":"print"},{"value":"2296-9365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}